evipedia.ai
← Back

NMN vs. NR for Health & Longevity

Evidence Review created on 09/29/2026 using AI4L / Opus 5.5

Also known as: Nicotinamide Mononucleotide vs. Nicotinamide Riboside, Nicotinamide Mononucleotide, NMN, β-Nicotinamide Mononucleotide, Beta-NMN, MIB-626, Nicotinamide Riboside, NR, Nicotinamide Ribonucleoside, Nicotinamide Riboside Chloride, NRC, Niagen, Tru Niagen

Motivation

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are two closely related forms of vitamin B3 sold as dietary supplements. Both are building blocks the body can use to make a molecule that every cell needs to turn food into energy and to repair damaged genetic material. Levels of that molecule fall with age, and refilling them has become one of the most discussed strategies in longevity science.

Interest grew from studies in aging mice that examined energy metabolism, blood vessel function and physical endurance after either compound was given. The two supplements are sold by competing companies and championed by rival research camps, each arguing that its molecule is absorbed or used more effectively. Human trials of each have multiplied, yet very few have tested the two side by side.

This review examines how the two compounds compare in people: how the body absorbs and processes them, which benefits and risks have been measured, how dosing protocols differ, and where the evidence is still missing for health- and longevity-focused adults weighing one against the other.

Benefits - Risks - Protocol - Conclusion

Expert commentary comparing NMN and NR as precursors of NAD+ (nicotinamide adenine dinucleotide, a coenzyme cells use for energy production and for repairing DNA, their genetic material).

Note: No Chris Kresser item is listed. His site offers only broad aging content, and his David Sinclair interview compares NMN and NR in a few sentences, too briefly for inclusion.

Grokipedia

  • NMN and NR

    A machine-written encyclopedia overview of both precursors covering biochemistry, research history and supplement use; useful orientation, though its claims need checking against the primary trials cited in this review.

Examine

  • Nicotinamide Mononucleotide

    Examine’s evidence-graded NMN page summarizing human trials, dosing and safety, and noting that longevity effects seen in animals remain unproven in humans.

  • Nicotinamide Riboside

    Examine’s NR page describing it as a vitamin B3 form converted to NAD+, with a research feed of human trials for comparison with the NMN page.

ConsumerLab

Systematic Reviews

Systematic reviews and meta-analyses comparing or separately assessing NMN and NR for function, cardiometabolic outcomes and safety.

No systematic review or meta-analysis dedicated to NR safety was found; the NR side of the risk comparison rests on individual randomized trials.

Mechanism of Action

NAD+ is used up by sirtuins (enzymes that remove acetyl tags from proteins to regulate metabolism and stress responses), PARPs (poly-ADP-ribose polymerases, DNA-repair enzymes) and CD38 (an immune-cell enzyme whose activity rises with age). Both supplements aim to refill the pool; critics counter that extra NAD+ may also fuel CD38 activity and tumor metabolism.

  • NR route: NR enters cells and becomes NMN via NRK1/2 (nicotinamide riboside kinases, enzymes that add a phosphate), then to NAD+ by NMNAT (the enzyme that joins NMN to an adenine group).
  • NMN route, contested: one camp holds that NMN must first be stripped to NR by CD73 (a cell-surface enzyme that removes phosphate) to enter cells; another reports a direct transporter encoded by the mouse gene Slc12a8 (Grozio et al., 2019), a claim disputed by ChromaDex adviser Brenner (Schmidt & Brenner, 2019).
  • Gut and liver conversion: much of either oral dose becomes nicotinamide in the gut and liver (Liu et al., 2018), and gut bacteria convert both to nicotinic acid (Shats et al., 2020). A Nestlé-sponsored human trial (Christen et al., 2026) proposes this shared route explains their comparable blood NAD+ rises.
  • Pharmacology: neither is receptor-selective; both feed NAD+ synthesis. Both leave plasma within hours; blood NAD+ builds over two weeks; the liver takes up most, muscle and brain less. Neither relies on CYP enzymes (liver drug-metabolizing enzymes); excess nicotinamide is tagged by NNMT (an enzyme that adds a methyl group for excretion) and oxidized to 2PY and 4PY (breakdown products).

Historical Context & Evolution

NAD+ was identified in 1906 as a helper molecule in yeast fermentation, and its vitamin B3 precursors, nicotinic acid and nicotinamide, were first used to cure pellagra (a deficiency disease of skin, gut and brain). NMN was characterized as an NAD+ intermediate in the 1950s, whereas NR was recognized as a human vitamin precursor only in 2004 (Bieganowski & Brenner, 2004).

Health-optimization interest arose when sirtuins were shown to depend on NAD+, linking the molecule to calorie-restriction biology. In mice, NMN reversed features of diet- and age-induced diabetes (Yoshino et al., 2011) and restored mitochondrial signaling in old animals in work led by Metro International Biotech co-founder David Sinclair (Gomes et al., 2013); NR extended remaining lifespan when started late (Zhang et al., 2016), and long-term NMN slowed physiological decline in a study co-authored by NMN producer Oriental Yeast (Mills et al., 2016). ChromaDex commercialized NR as Niagen with Charles Brenner as scientific adviser, while David Sinclair’s advocacy popularized NMN, creating two commercial camps.

Newer evidence has cut both ways. The Interventions Testing Program found no lifespan extension with NR (Harrison et al., 2021), and a systematic review of human trials found rising blood NAD+ with mixed functional results (Gallagher & Emmanuel, 2026). Regulators excluded NMN from United States supplements in 2022 because a drug form was under investigation, then reversed in 2025. The first head-to-head trial (Christen et al., 2026) and microbial findings have shifted debate from which molecule enters cells better toward whether raising NAD+ yields clinical benefit.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no functional outcome or validated clinical surrogate has been replicated consistently across independent trials of either compound, and the only head-to-head human trial (Christen et al., 2026) measured blood NAD+, an unvalidated biomarker.

Medium 🟩 🟩

Blood Pressure

Two meta-analyses of NMN randomized trials found a small diastolic reduction (Zhang et al., 2026; Yang et al., 2026), and a trial co-authored by developer Metro International Biotech found the largest single-trial drop (Pencina et al., 2023). Most individual NMN trials were too small to show it alone. NR hinted at lower pressure early (Martens et al., 2018), but later NR trials found none (Lin et al., 2025; Martens et al., 2026), so the benefit is shown for NMN only.

Magnitude: NMN diastolic −2.15 mmHg (95% confidence interval, the range likely to contain the true effect, −3.68 to −0.61) and systolic −3.94 mmHg in adults aged 60 and older (Zhang et al., 2026); NR 1,000 mg/day with walking did not lower daytime systolic pressure more than placebo with walking (Lin et al., 2025).

Low 🟩

Walking Endurance and Aerobic Capacity ⚠️ Conflicted

NMN improved endurance (Gao et al., 2026), including a trial by NMN maker Abinopharm (Yi et al., 2023); NR improved six-minute walk in peripheral artery disease (narrowed leg arteries) (McDermott et al., 2024). Trials showed no muscle or gait gains (Prokopidis et al., 2025). Net: endurance may improve, not strength.

Magnitude: NMN endurance standardized mean difference (effect size in standard-deviation units) 0.66 at medium and 1.02 at high doses (Gao et al., 2026); NR +17.6 m six-minute walk distance versus placebo in peripheral artery disease (McDermott et al., 2024).

Insulin Sensitivity and Blood Lipids ⚠️ Conflicted

NMN raised insulin sensitivity in prediabetic women (Yoshino et al., 2021) and once lowered LDL (“bad” artery-clogging) cholesterol (Pencina et al., 2023); pooled NMN trials found neither (Chen et al., 2024), nor did NR in a trial co-authored by ChromaDex adviser Brenner (Dollerup et al., 2018). Net: no consistent benefit.

Magnitude: NMN raised insulin-stimulated glucose uptake by about 25% in 13 treated women (Yoshino et al., 2021) and lowered LDL cholesterol by 18.7 mg/dL (Pencina et al., 2023); NR 2,000 mg/day left insulin sensitivity unchanged (Dollerup et al., 2018).

Arterial Stiffness

NR improved arterial stiffness in Werner syndrome (an inherited premature-aging disorder) (Shoji et al., 2025), and trended lower in healthy older adults (Martens et al., 2018). NMN produced a non-significant downward trend in a trial by supplement maker DHC (Katayoshi et al., 2023).

Magnitude: In nine Werner syndrome patients, NR changed the cardio-ankle vascular index (an arterial-stiffness score) by −0.4 to −0.5 versus +0.7 to +0.9 on placebo (Shoji et al., 2025); changes in healthy adults did not reach statistical significance (Martens et al., 2018; Katayoshi et al., 2023).

Self-Rated Health and Sleep ⚠️ Conflicted

NMN improved self-rated quality of life in pooled trials (Gao et al., 2026) and sleep scores in a trial run by maker Meiji (Morifuji et al., 2024), yet no precursor improved pooled fatigue or sleep. NR data are sparse. Net: modest, inconsistent subjective gains, for NMN only.

Magnitude: NMN quality-of-life standardized mean difference 0.45–0.56; perceived fatigue and sleep showed no significant effect for any precursor (Gao et al., 2026).

Brain Health and Neurodegeneration ⚠️ Conflicted

NR raised brain NAD+ in a small Parkinson’s trial (Brakedal et al., 2022) but left cognition unchanged in two mild cognitive impairment (pre-dementia thinking decline) trials, one co-authored by ChromaDex adviser Brenner (Orr et al., 2024; Martens et al., 2026). NMN is untested. Net: no demonstrated cognitive benefit.

Magnitude: NR 1 g/day for 10–12 weeks left cognitive scores unchanged versus placebo (Orr et al., 2024; Martens et al., 2026); Parkinson’s rating improvements with high-dose NR were confounded by medication timing, and the abstracts report no outcome figure (Berven et al., 2023).

Immune Thrombocytopenia ⭕️ Not Central to Health & Longevity

Low-dose NMN produced platelet responses in steroid-resistant immune thrombocytopenia (an autoimmune low-platelet disorder) in a trial without a placebo group (Li et al., 2026). This bears on autoimmune disease treatment, not healthy aging; NR was not tested.

Magnitude: 20% met the primary platelet-response endpoint and 60% exceeded 1.5 times baseline platelet counts (Li et al., 2026).

Speculative 🟨

Higher Cellular NAD+ Levels

NR and NMN raised blood NAD+ comparably in the only head-to-head trial (Christen et al., 2026). Blood NAD+ is an unvalidated biomarker; the basis for tissue or clinical benefit is mechanistic.

Lifespan Extension

NR extended late-life mouse lifespan in one study (Zhang et al., 2016) but not in the Interventions Testing Program (Harrison et al., 2021). The basis is animal data only; no human lifespan data exist.

Slower Biological-Age Clocks

NR lowered age estimates based on chemical tags on DNA in exploratory analyses (Orr et al., 2024), and NMN held a blood-based age score steady (Yi et al., 2023). The basis is unvalidated biomarkers only.

Reduced Inflammatory Signaling

In an Elysium-co-authored trial, NR roughly halved airway interleukin-8 (an inflammatory signal) in chronic lung disease (Norheim et al., 2024). The basis is unvalidated biomarkers; no clinical inflammation outcome was shown.

Ovarian and Egg-Cell Quality ⭕️ Not Central to Health & Longevity

A systematic review found NMN improved egg-cell quality in animal and laboratory models (Noh et al., 2026). This bears on fertility, not longevity, and the basis is non-human data only.

Benefit-Modifying Factors

  • Genetic polymorphisms: No pharmacogenetic studies exist. Variants in NAMPT (the recycling enzyme that rebuilds NAD+ from nicotinamide) or NNMT could shift how much of either precursor becomes NAD+ rather than waste metabolites.
  • Baseline NAD+ and blood markers: In an NMN trial co-authored by maker Abinopharm, baseline blood NAD+ tracked lipid, liver and immune markers (Kuerec et al., 2026); people with low starting NAD+ are hypothesized, but not shown, to benefit more.
  • Sex: The NMN insulin-sensitivity signal came from women only; developer Metro International Biotech’s pharmaceutical NMN raised NAD+ equally in men and women (Pencina et al., 2023). No sex-specific NR benefit has been reported.
  • Pre-existing conditions: Functional gains appeared mainly in impaired groups: NR in peripheral artery disease, NMN in prediabetes. Healthy, fit adults and people with mild cognitive impairment showed little benefit.
  • Age: NMN’s systolic blood-pressure effect was confined to adults aged 60 and older (Zhang et al., 2026), while muscle outcomes stayed null above 60 for both compounds (Prokopidis et al., 2025).

Potential Risks & Side Effects

High 🟥 🟥 🟥

Mild Gastrointestinal and Nonspecific Adverse Events

Trial participants on either compound occasionally report nausea, bloating, loose stools, headache or fatigue, at rates similar to placebo. For NMN, a meta-analysis of randomized trials at 250–2,000 mg/day found no increase in overall, serious or withdrawal-causing adverse events versus placebo (Yang et al., 2026). For NR, a ChromaDex-authored trial at up to 1,000 mg/day (Conze et al., 2019) and 3,000 mg/day for four weeks (Berven et al., 2023) showed no excess events, and neither compound causes niacin-type flushing. Data beyond one year are lacking.

Magnitude: Adverse-event rates did not differ significantly from placebo in pooled NMN trials (Yang et al., 2026); in an NMN trial in immune thrombocytopenia, mild treatment-related events occurred in 12% (Li et al., 2026).

Medium 🟥 🟥

No risk reaches Medium: beyond the pooled adverse-event data, the remaining signals come from observational metabolite associations, conflicting pooled trials driven by a different vitamin B3 form, single-trial subgroup findings, or animal and cell models.

Low 🟥

Cardiovascular Risk from the Metabolite 4PY

Both are cleared as 2PY and 4PY, which NMN raises dose-dependently (Irie et al., 2020). In cohorts, higher 4PY predicted major cardiovascular events, and 4PY inflamed mouse vessels (Ferrell et al., 2024); high-dose NR raised 4PY and enlarged plaques in cholesterol-prone mice (Wang et al., 2025). Human causality is unproven.

Magnitude: 4PY adjusted hazard ratio (relative risk over time) of 1.89 and 1.99 for three-year major cardiovascular events in two cohorts (Ferrell et al., 2024); no supplement trial has measured cardiovascular events.

Blood Glucose Elevation ⚠️ Conflicted

Pooled vitamin B3 precursor trials show small rises in glucose and HbA1c (three-month average blood sugar), driven mainly by nicotinic acid (Sohouli et al., 2024); pooled NMN trials show no change (Chen et al., 2024). Net: the risk appears confined to nicotinic acid.

Magnitude: All precursors pooled raised glucose by 2.17 mg/dL and HbA1c by 0.11 percentage points (Sohouli et al., 2024); NMN alone produced no significant change (Chen et al., 2024).

Blunted Physical Gains in Cognitive Impairment

In older adults with mild cognitive impairment, walking speed improved on placebo but not on NR (Orr et al., 2024). This comes from one small trial; NMN was not tested in this group.

Magnitude: Direction favors placebo for walking speed over 10 weeks; the abstract reports no between-group outcome figure (Orr et al., 2024).

Speculative 🟨

Tumor Growth and Metastasis

NR increased breast-cancer occurrence and brain metastasis (spread) in mice (Maric et al., 2023), and NAD+ fuels inflammatory secretions of aging cells (Nacarelli et al., 2019). The basis is animal and cell data only.

Homocysteine Elevation

NR 3,000 mg/day briefly raised homocysteine (a vascular-risk amino acid that builds when folate-like methyl donors run short) (Berven et al., 2023), unlike 1,000 mg/day (Conze et al., 2019). The basis is biomarkers only.

Risk-Modifying Factors

  • Genetic polymorphisms: Reduced-function MTHFR (an enzyme that activates folate for methylation) variants or high NNMT activity may amplify methyl-donor drain; a common variant associated with higher 2PY and 4PY levels has been identified (Ferrell et al., 2024).
  • Baseline homocysteine and kidney function: Elevated homocysteine, or low eGFR (estimated glomerular filtration rate, a kidney-function measure), may raise risk, because 2PY and 4PY are cleared by the kidneys.
  • Sex: No sex-based adverse-event differences have been reported for either compound; pregnancy and breastfeeding remain unstudied.
  • Pre-existing conditions: Active or past cancer (tumor-fueling concern), established atherosclerosis (artery plaque buildup; 4PY and plaque signals) and mild cognitive impairment (blunted physical gains) carry higher potential risk.
  • Age: Adults in their 70s and 80s carry higher baseline cardiovascular and cancer risk, raising the stakes of the 4PY and tumor signals; trials in adults over 80 are scarce.

Key Interactions & Contraindications

  • Prescription – cancer therapies (PARP inhibitors such as olaparib and niraparib; chemotherapy such as cyclophosphamide): Caution. Extra NAD+ could theoretically support tumor metabolism or blunt drugs that exploit tumor NAD+ stress. Mitigation: pausing either compound during active treatment unless the oncologist agrees.
  • Prescription – blood-pressure medications (lisinopril, amlodipine, losartan): Monitor. NMN’s small diastolic reduction may add to drug effects, with light-headedness possible. Mitigation: home blood-pressure checks during the first four weeks.
  • Prescription – methotrexate (an antifolate drug): Monitor. Nicotinamide clearance and methotrexate both strain folate and methyl-donor supply, possibly raising homocysteine. Mitigation: homocysteine and folate check after eight weeks.
  • Over-the-counter – vitamin B3 (niacin, nicotinamide, NADH products): Caution. Combining these products raises total nicotinamide load, 2PY, 4PY and methyl demand; niacin adds flushing and glucose rise. Mitigation: counting every vitamin B3 source and avoiding concurrent use.
  • Supplements – blood-pressure-lowering agents (fish oil, magnesium, beetroot nitrate, garlic): Monitor. Additive but small reductions with NMN; dizziness is unlikely. Mitigation: periodic home blood-pressure checks.
  • Supplements – resveratrol and pterostilbene: Minimal. Commonly paired with NR, but resveratrol added no walking benefit to NR in peripheral artery disease (McDermott et al., 2024). Mitigation: no added benefit, so pairing is optional.
  • Supplements – methyl donors (betaine, methylfolate, vitamin B12): Favorable. They may offset methyl-donor drain and homocysteine rise, though no trial has tested this. Mitigation: most relevant when homocysteine exceeds 10 µmol/L.
  • Other interventions – NMN plus NR together: Caution. Both converge on the same pathway, so combining adds cost and methyl load without shown benefit. Mitigation: using one compound only.
  • Other interventions – exercise training: Potentiating for NMN. NMN with training raised ventilatory thresholds (intensities where breathing rises sharply) more than training alone (Liao et al., 2021); NR plus walking did not lower blood pressure further (Lin et al., 2025).

Populations who should avoid NMN vs. NR:

  • Pregnant or breastfeeding women (no human safety data)
  • Children and adolescents under 18 (no long-term safety data)
  • People with active cancer or cancer treated within the past 5 years, unless cleared by their oncologist
  • People with chronic kidney disease stage 4–5 (eGFR below 30 mL/min/1.73 m²), in whom 2PY and 4PY accumulate

Risk Mitigation Strategies

  • Low starting dose with titration: starting at NR 250–300 mg or NMN 250 mg daily, increasing every 2 weeks toward 1,000 mg/day if tolerated, to limit nausea, bloating and headache.
  • Dose ceiling: staying at or below 1,000 mg/day for routine use, the range with the most safety data, to limit 4PY accumulation and methyl-donor drain.
  • Homocysteine check: measuring homocysteine at baseline and after 8–12 weeks, with methylfolate, vitamin B12 or betaine added if it rises above 10 µmol/L, offsets methyl-donor drain.
  • Cancer screening up to date: completing age-appropriate cancer screening before starting and keeping it current, given the animal signal that NAD+ may fuel tumor growth.
  • One compound only: using either NMN or NR, not both, to avoid doubling nicotinamide load, 4PY exposure and methyl demand.
  • Third-party-tested products: choosing products with independent potency and purity testing to avoid underdosed or contaminated supplements, a larger concern for NMN.
  • Scheduled reassessment: reviewing blood pressure, glucose, lipids and kidney function at 3 months and stopping if adverse trends appear, limiting unrecognized metabolic or cardiovascular harm.

Therapeutic Protocol

  • NR regimen: 300–1,000 mg/day of NR chloride, usually 500 mg twice daily in trials (McDermott et al., 2024); popularized by Charles Brenner and ChromaDex (Tru Niagen).
  • NMN regimen: 250–1,000 mg/day; 600 mg/day gave peak blood NAD+ and walking gains in one dose-finding trial (Yi et al., 2023); popularized by David Sinclair, who reports taking about 1 g each morning.
  • Matched-dose comparison: at equal gram doses, NR and NMN raised blood NAD+ comparably over 14 days (Christen et al., 2026); per milligram, NR chloride supplies about 15% more precursor molecules than NMN.
  • Alternative approaches: NR plus pterostilbene (Elysium Basis, associated with Leonard Guarente), sublingual (under-the-tongue) NMN, intravenous NAD+ offered by infusion clinics without outcome trials (Gallagher & Emmanuel, 2026), and low-cost nicotinamide or niacin are the main alternatives.
  • Time of day: morning dosing is common; however, afternoon NMN improved leg function and drowsiness more than morning NMN in older adults, in a trial co-authored by NMN supplier Mitsubishi Corporation Life Sciences (Kim et al., 2022).
  • Half-life: both parent compounds clear from plasma within hours, but blood NAD+ rises within two weeks and stays elevated during continued dosing (Conze et al., 2019).
  • Single versus split dosing: NR trials usually split doses twice daily; NMN is typically taken once daily, though twice-daily pharmaceutical NMN roughly doubled exposure (Pencina et al., 2023).
  • Genetic polymorphisms: no genotype-guided dosing exists; carriers of reduced-function MTHFR variants may favor the lower dose range with methyl-donor support.
  • Sex: no sex-based dose differences are established; NAD+ responses to pharmaceutical NMN did not differ between men and women (Pencina et al., 2023).
  • Age: trials in adults aged 55–80 used standard doses; blood-pressure gains with NMN appeared only at 60 and older, and dosing data for adults over 80 are scarce.
  • Baseline biomarkers: elevated homocysteine favors lower doses with methyl donors; elevated blood pressure or prediabetes defines groups where NMN signals appeared.
  • Pre-existing conditions: trials in peripheral artery disease used NR 1,000 mg/day; prediabetes trials used NMN 250 mg/day; cancer history favors avoidance.

Discontinuation & Cycling

  • Intended duration: used as ongoing supplements, but the longest controlled trials lasted 6–12 months, so lifelong safety of either compound is unestablished.
  • Withdrawal effects: none reported for either compound; blood NAD+ is expected to drift back toward baseline after stopping, although the NR airway-inflammation reduction persisted 12 weeks post-treatment (Norheim et al., 2024).
  • Tapering: not required; either compound can be stopped abruptly because no rebound or dependence has been observed.
  • Cycling: no trial supports cycling for efficacy; some users take weekends off to limit methyl-donor demand, an untested practice.
  • Switching between compounds: switching from NMN to NR or back can occur directly without overlap, since both feed the same NAD+ pool.

Sourcing and Quality

  • NR form and supply: NR chloride is sold mainly as ChromaDex’s Niagen (in Tru Niagen), which holds generally-recognized-as-safe status and supplement notifications in the United States; Elysium Basis uses its own NR supply. Few manufacturers exist, giving relatively uniform quality.
  • NMN form and supply: only β-NMN is the active form; many unbranded manufacturers exist, so purity varies more than with NR. Certificates of analysis report purity from laboratory testing, with established suppliers typically citing at least 98%.
  • Third-party testing: independent seals from USP (United States Pharmacopeia) or NSF (NSF International, a product-certification body), or ConsumerLab testing confirm label potency and screen for heavy metals and microbes, relevant to both compounds.
  • Stability and storage: both compounds degrade with heat and moisture; sealed containers stored cool and dry preserve potency.
  • Delivery forms: sublingual NMN raised terminal metabolites 2PY and 4PY faster than oral NMN without shown benefit in a Meiji-run trial (Wakabayashi et al., 2026); liposomal forms lack comparative data.
  • Reputable brands: Tru Niagen (NR), Elysium Basis (NR plus pterostilbene) and Life Extension NAD+ Cell Regenerator (NR) are established; for NMN, some brands publish batch-level third-party certificates that allow purity to be checked. Pharmaceutical NMN (MIB-626) is not sold commercially.

Practical Considerations

  • Time to effect: blood NAD+ rises within 1–2 weeks; functional changes in trials were measured after 6 weeks to 6 months, so early subjective “energy” reports are unreliable.
  • Common pitfalls: combining NMN with NR or niacin, buying untested NMN, expecting felt effects, neglecting exercise, and ignoring homocysteine and kidney status.
  • Regulatory status: the United States Food and Drug Administration excluded NMN from supplements in 2022, then reversed in September 2025 after pressure from the Natural Products Association, a trade group whose members earn revenue from NMN sales.
  • Cost and access: both are widely available and not exceptionally expensive; neither is reimbursed by insurers, so payer incentives do not favor one, and the financial interests shaping research lie with manufacturers.
  • Choosing between them: NR has more and longer independent randomized trials, including disease populations; NMN has more small, manufacturer-funded functional trials. Direct comparison shows similar blood NAD+ effects (Christen et al., 2026).

Interaction with Foundational Habits

  • Sleep: Direction possibly potentiating, NMN only. NMN improved sleep-questionnaire scores (Morifuji et al., 2024) and reduced afternoon drowsiness when dosed later (Kim et al., 2022); NAD+ links to the body clock through sirtuins. No sleep disruption has been reported for either compound.
  • Nutrition: Indirect. Diet supplies vitamin B3 and tryptophan, both NAD+ sources, and methyl donors (leafy greens, eggs, legumes) support clearance of excess nicotinamide. Heavy alcohol intake consumes NAD+. Neither compound depletes other nutrients, apart from possible methyl-donor demand.
  • Exercise: Potentiating for NMN, none shown for NR. NMN with running training improved ventilatory thresholds (Liao et al., 2021), while NR added no blood-pressure benefit to walking (Lin et al., 2025). A meta-analysis shows exercise itself raises NAMPT, the NAD+ recycling enzyme (Sun et al., 2023).
  • Stress management: None shown. No human data link either compound to cortisol or stress response, and pooled trials found no reduction in perceived fatigue (Gao et al., 2026).

Monitoring Protocol & Defining Success

Baseline testing before starting either compound establishes a reference point: blood pressure, fasting glucose and HbA1c, a lipid panel, liver enzymes, kidney function, homocysteine and high-sensitivity C-reactive protein, with optional whole-blood NAD+ and a timed six-minute walk or aerobic fitness test. Because NR and NMN differ little in blood NAD+ response, the same panel serves both.

Ongoing monitoring follows a set cadence: repeat blood pressure weekly at home for the first four weeks, repeat homocysteine and the metabolic panel at 8–12 weeks, then every 6–12 months while supplementation continues. Success means stable or improved blood pressure, walking capacity and metabolic markers without rises in homocysteine, glucose or kidney markers; no change after six months suggests limited personal benefit.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Blood pressure ~115/75 mmHg or lower Tracks NMN’s modest diastolic effect Home readings, seated, morning; conventional target below 130/80 mmHg
Homocysteine 5–8 µmol/L Flags methyl-donor drain Fasting; conventional upper limit ~15 µmol/L; best paired with folate and vitamin B12
Fasting glucose 75–90 mg/dL Detects glucose rise Fasting 8–12 hours; conventional normal below 100 mg/dL
HbA1c Below 5.4% Longer-term glucose trend Conventional normal below 5.7%; no fasting needed
LDL cholesterol or ApoB LDL below 100 mg/dL; ApoB below 80 mg/dL Tracks lipid effects ApoB (apolipoprotein B, the main protein on artery-clogging cholesterol particles) is more precise; conventional LDL below 130 mg/dL
ALT and AST ALT below 25 U/L; AST below 25 U/L Confirms liver tolerance ALT and AST are liver enzymes; conventional upper limits ~40 U/L; hard exercise in the prior 48 hours can raise values
Creatinine and eGFR eGFR above 90 mL/min/1.73 m² Kidneys clear 2PY and 4PY Conventional normal eGFR above 60 mL/min/1.73 m²; a high-meat meal the day before can raise creatinine; cystatin C (a kidney-function blood test less affected by muscle mass) is a useful pairing in muscular adults
hs-CRP Below 1.0 mg/L General inflammation trend hs-CRP is high-sensitivity C-reactive protein; conventional low risk below 3.0 mg/L; acute illness temporarily raises values
Whole-blood NAD+ No established target; track change from own baseline Confirms absorption Specialty test; morning draw at consistent timing relative to dose
Six-minute walk distance No established target; track change from own baseline Functional endurance Same course and time of day each test

Qualitative markers to track:

  • Energy levels through the day and afternoon drowsiness
  • Sleep quality and daytime alertness
  • Exercise tolerance and recovery after endurance sessions
  • Gastrointestinal comfort (nausea, bloating, stool changes)
  • Cognitive clarity and mood

Emerging Research

  • Head-to-head clinical comparison: a phase 2 trial of 138 patients with glaucoma (optic-nerve damage causing vision loss) compares NR, NMN, nicotinamide, nicotinic acid and placebo for two weeks, with visual-field sensitivity as primary endpoint (NCT06991712); it is the first clinical-outcome comparison of the two precursors.
  • Frailty and gait speed: the NADage phase 2 trial gives 100 older adults NR 2,000 mg/day or placebo for one year, with change in gait speed as primary outcome (NCT06208527).
  • Parkinson’s disease progression: the completed NOPARK phase 3 trial randomized 410 people with early Parkinson’s to NR 500 mg twice daily or placebo for 52 weeks (NCT03568968); unpublished results could strengthen or weaken the neuroprotection case.
  • Confirmatory walking trial: NICE-PAD II, a phase 3 trial of 250 people with peripheral artery disease, tests NR 1,000 mg/day against placebo on six-minute walk distance (NCT07782671), aiming to confirm or refute earlier gains.
  • NMN and biological age: a 240-person trial gives NMN 350 mg/day or placebo for one year, with biological-age measures as primary outcome (NCT06592859).
  • Precursor fate tracing: a phase 1 trial by Metro International Biotech, developer of pharmaceutical NMN, traces the metabolic fate of labeled NMN versus nicotinamide in 32 adults (NCT06882096).
  • Cardiovascular safety of 4PY: observational links between 4PY and cardiovascular events (Ferrell et al., 2024) mean future NR and NMN trials measuring 4PY and vascular inflammation could weaken the safety case.
  • Gut microbiome as mediator: evidence that gut bacteria convert both precursors to nicotinic acid (Christen et al., 2026) suggests individual microbiome composition may determine response, a hypothesis future stratified trials could test.

Conclusion

Nicotinamide mononucleotide and nicotinamide riboside are two closely related forms of vitamin B3 that the body turns into the same molecule used for energy and repair. When compared directly, they raised its blood levels about equally, and much of each dose seems to be reshaped by gut bacteria and the liver before reaching tissues. The long-running argument over which one enters cells better therefore matters less than it once appeared.

For health-focused adults, the more relevant question is what either one achieves. Human studies point to modest gains in walking endurance, a small blood-pressure drop seen so far only with the mononucleotide, and some self-reported well-being improvements. They do not show gains in muscle size, strength or thinking skills, effects on blood sugar control and cholesterol are inconsistent across studies, and no study shows either extends human life. The riboside has more and longer independent studies, including in people with narrowed leg arteries; the mononucleotide has more small studies run by its makers.

Short-term safety looks good for both. Open questions concern breakdown products linked to heart risk, extra strain on the body’s system for clearing surplus vitamin B3, and animal findings that extra fuel may help some cancers grow.

Much of this research is funded or carried out by companies that sell these products or develop drug versions of them, and a supplement trade group whose members profit from sales led the legal push that restored the mononucleotide to the United States supplement market.

Top - Benefits - Risks - Protocol